Search This Blog

Thursday, September 13, 2018

A wearable device for regrowing hair


Although some people embrace the saying “bald is beautiful,” for others, alopecia, or excessive hair loss, can cause stress and anxiety. Some studies have shown that stimulating the skin with lasers can help regrow hair, but the equipment is often large, consumes lots of energy and is difficult to use in daily life. Now, researchers have developed a flexible, wearable photostimulator that speeds up hair growth in mice. They report their results in ACS Nano.
Affecting millions of men and women worldwide, alopecia has several known causes, including heredity, stress, aging and elevated male hormones. Common treatments include medications, such as minoxidil, corticosteroid injections and hair transplant surgery. In addition, irradiating the bald area with a red laser can stimulate hair follicles, causing cells to proliferate. However, this treatment is often impractical for home use. So, Keon Jae Lee and colleagues wanted to develop a flexible, durable photostimulator that could be worn on human skin.
The team fabricated an ultrathin array of flexible vertical micro-light-emitting diodes (μLEDs). The array consisted of 900 red μLEDs on a chip slightly smaller than a postage stamp and only 20 μm thick. The device used almost 1,000 times less power per unit area than a conventional phototherapeutic laser, and it did not heat up enough to cause thermal damage to human skin. The array was sturdy and flexible, enduring up to 10,000 cycles of bending and unbending. The researchers tested the device’s ability to regrow hair on mice with shaved backs. Compared with untreated mice or those receiving minoxidil injections, the mice treated with the μLED patch for 15 minutes a day for 20 days showed significantly faster hair growth, a wider regrowth area and longer hairs.
Story Source:
Materials provided by American Chemical SocietyNote: Content may be edited for style and length.

Journal Reference:
  1. Han Eol Lee, Seung Hyun Lee, Minju Jeong, Jung Ho Shin, Yuri Ahn, Daesoo Kim, Sang Ho Oh, Seok Hyun Yun, Keon Jae Lee. Trichogenic Photostimulation Using Monolithic Flexible Vertical AlGaInP Light-Emitting DiodesACS Nano, 2018; DOI: 10.1021/acsnano.8b05568

Wearable ultrasound patch monitors blood pressure deep inside body


Wearable ultrasound patch tracks blood pressure in a deep artery or vein.
Credit: Chonghe Wang/Nature Biomedical Engineering
A new wearable ultrasound patch that non-invasively monitors blood pressure in arteries deep beneath the skin could help people detect cardiovascular problems earlier on and with greater precision. In tests, the patch performed as well as some clinical methods to measure blood pressure.
Applications include real-time, continuous monitoring of blood pressure changes in patients with heart or lung disease, as well as patients who are critically ill or undergoing surgery. The patch uses ultrasound, so it could potentially be used to non-invasively track other vital signs and physiological signals from places deep inside the body.
A team of researchers led by the University of California San Diego describe their work in a paper published Sept. 11 in Nature Biomedical Engineering.
“Wearable devices have so far been limited to sensing signals either on the surface of the skin or right beneath it. But this is like seeing just the tip of the iceberg,” said Sheng Xu, a professor of nanoengineering at the UC San Diego Jacobs School of Engineering and the corresponding author of the study. “By integrating ultrasound technology into wearables, we can start to capture a whole lot of other signals, biological events and activities going on way below the surface in a non-invasive manner.”
“We are adding a third dimension to the sensing range of wearable electronics,” said Xu, who is also affiliated with the Center for Wearable Sensors at UC San Diego.
The new ultrasound patch can continuously monitor central blood pressure in major arteries as deep as four centimeters (more than one inch) below the skin.
Physicians involved with the study say the technology would be useful in various inpatient procedures.
“This has the potential to be a great addition to cardiovascular medicine,” said Dr. Brady Huang, a co-author on the paper and radiologist at UC San Diego Health. “In the operating room, especially in complex cardiopulmonary procedures, accurate real-time assessment of central blood pressure is needed — this is where this device has the potential to supplant traditional methods.”
A convenient alternative to clinical methods
The device measures central blood pressure — which differs from the blood pressure that’s measured with an inflatable cuff strapped around the upper arm, known as peripheral blood pressure. Central blood pressure is the pressure in the central blood vessels, which send blood directly from the heart to other major organs throughout the body. Medical experts consider central blood pressure more accurate than peripheral blood pressure and also say it’s better at predicting heart disease.
Measuring central blood pressure isn’t typically done in routine exams, however. The state-of-the-art clinical method is invasive, involving a catheter inserted into a blood vessel in a patient’s arm, groin or neck and guiding it to the heart.
A non-invasive method exists, but it can’t consistently produce accurate readings. It involves holding a pen-like probe, called a tonometer, on the skin directly above a major blood vessel. To get a good reading, the tonometer must be held steady, at just the right angle and with the right amount of pressure each time. But this can vary between tests and different technicians.
“It’s highly operator-dependent. Even with the proper technique, if you move the tonometer tip just a millimeter off, the data get distorted. And if you push the tonometer down too hard, it’ll put too much pressure on the vessel, which also affects the data,” said co-first author Chonghe Wang, a nanoengineering graduate student at UC San Diego. Tonometers also require the patient to sit still — which makes continuous monitoring difficult — and are not sensitive enough to get good readings through fatty tissue.
The UC San Diego-led team has developed a convenient alternative — a soft, stretchy ultrasound patch that can be worn on the skin and provide accurate, precise readings of central blood pressure each time, even while the user is moving. And it can still get a good reading through fatty tissue.
The patch was tested on a male subject, who wore it on the forearm, wrist, neck and foot. Tests were performed both while the subject was stationary and during exercise. Recordings collected with the patch were more consistent and precise than recordings from a commercial tonometer. The patch recordings were also comparable to those collected with a traditional ultrasound probe.
Making ultrasound wearable
“A major advance of this work is it transforms ultrasound technology into a wearable platform. This is important because now we can start to do continuous, non-invasive monitoring of major blood vessels deep underneath the skin, not just in shallow tissues,” said Wang.
The patch is a thin sheet of silicone elastomer patterned with what’s called an “island-bridge” structure — an array of small electronic parts (islands) that are each connected by spring-shaped wires (bridges). Each island contains electrodes and devices called piezoelectric transducers, which produce ultrasound waves when electricity passes through them. The bridges connecting them are made of thin, spring-like copper wires. The island-bridge structure allows the entire patch to conform to the skin and stretch, bend and twist without compromising electronic function.
The patch uses ultrasound waves to continuously record the diameter of a pulsing blood vessel located as deep as four centimeters below the skin. This information then gets translated into a waveform using customized software. Each peak, valley and notch in the waveform, as well as the overall shape of the waveform, represents a specific activity or event in the heart. These signals provide a lot of detailed information to doctors assessing a patient’s cardiovascular health. They can be used to predict heart failure, determine if blood supply is fine, etc.
Next steps
Researchers note that the patch still has a long way to go before it reaches the clinic. Improvements include integrating a power source, data processing units and wireless communication capability into the patch.
“Right now, these capabilities have to be delivered by wires from external devices. If we want to move this from benchtop to bedside, we need to put all these components on board,” said Xu.
The team is looking to collaborate with experts in data processing and wireless technologies for the next phase of the project.
Story Source:
Materials provided by University of California – San DiegoNote: Content may be edited for style and length.

Journal Reference:
  1. Chonghe Wang, Xiaoshi Li, Hongjie Hu, Lin Zhang, Zhenlong Huang, Muyang Lin, Zhuorui Zhang, Zhenan Yin, Brady Huang, Hua Gong, Shubha Bhaskaran, Yue Gu, Mitsutoshi Makihata, Yuxuan Guo, Yusheng Lei, Yimu Chen, Chunfeng Wang, Yang Li, Tianjiao Zhang, Zeyu Chen, Albert P. Pisano, Liangfang Zhang, Qifa Zhou, Sheng Xu. Monitoring of the central blood pressure waveform via a conformal ultrasonic deviceNature Biomedical Engineering, 2018; 2 (9): 687 DOI: 10.1038/s41551-018-0287-x

Supernus Pharma to acquire Biscayne Neurotherapeutics for up to $185M


Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire privately held Biscayne Neurotherapeutics, a developer of a novel treatment for epilepsy, now called SPN-817.
Under the terms of the deal, Supernus will pay $15M upfront, up to $75M in development milestones and up to $95M in sales milestones. Biscayne will also be eligible for low single-digit royalties on net sales. Supernus will be responsible for any applicable royalties to third parties for the use of in-licensed intellectual property, up to a maximum of 12% for all parties.

Galapagos,MorphoSys start study of subcutaneous bridging with MOR106


Galapagos (GLPG) and MorphoSys (MOR) announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, randomized, open-label study in healthy volunteers who will be treated with different single dose levels of MOR106 administered subcutaneously or intravenously. Part 2 is a multiple center, randomized, placebo-controlled, multiple dose study in patients with moderate to severe atopic dermatitis who will be treated subcutaneously for 12 weeks. “The start of the bridging study together with Galapagos with a subcutaneous formulation of MOR106 is an important milestone in its clinical development,” commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG. “This route of subcutaneous administration is widely used for the treatment of chronic skin diseases, and we intend to evaluate it in this study with the goal of providing support for the further clinical development of MOR106.” “This study represents the next important step in our strategy to progress MOR106 rapidly in the clinic and is expected to provide additional insights into patient response, while we await the results of our ongoing IGUANA Phase 2 trial with MOR106 in atopic dermatitis patients,” said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos.
https://thefly.com/landingPageNews.php?id=2790335

Pacira, Heron Therapeutics initiated at Stifel


Pacira initiated with a Sell at Stifel. Stifel analyst Derek Archila initiated Pacira (PCRX) with a Sell rating and a price target of $41, saying the stock price is not “particularly cheap” following the rally driven by an upward revision to Exparel sales guidance during its Q2 earnings call. The analyst adds that the approval of Heron’s (HRTX) HTX-011 also creates a “medium- to long-term headwind” for Pacira.
https://thefly.com/landingPageNews.php?id=2790371

Globus Medical acquires Nemaris, developer and marketer of Surgimap


Globus Medical announced the acquisition of Nemaris, a privately held company that markets and develops Surgimap, a leading surgical planning software platform. Surgimap allows healthcare professionals to simulate potential surgical outcomes and share medical imaging globally to improve procedural workflow and patient care.
https://thefly.com/landingPageNews.php?id=2790375

Heron Therapeutics initiated at Stifel


Heron Therapeutics initiated with a Buy at Stifel. Stifel analyst Derek Archila initiated Heron Therapeutics with a Buy rating and a price target of $55. The analyst expects the company’s HTX-011 to be approved for the prevention of postsurgical pain, becoming “the first product to receive an opioid sparing indication from the FDA”. Archila adds that shares could be driven higher amid the “continued discussion about potential legislation to unbundle branded non-opioid analgesic”.
https://thefly.com/landingPageNews.php?id=2790377